<DOC>
	<DOCNO>NCT01722227</DOCNO>
	<brief_summary>This first prospective randomize double-blind placebo-controlled study investigate effect GLP-1 analog , specifically liraglutide , blood glucose level variability subject type 1 diabetes treat insulin . Liraglutide preferred GLP-1 analog study pharmacokinetics pharmacodynamics drug consistent sustain duration action . The current gold standard management type 1 diabetes base insulin replacement novel analog specify pharmacodynamic profile unique insulin delivery system ( insulin pump therapy ) . No adjuvant therapy demonstrate sustained benefit population . This study also investigate effect liraglutide suppression glucagon secretion meal challenge . This particular importance since , absence insulin secretion β-cell , paracrine inhibition glucagon secretion α-cell . Dysregulation glucagon secretion may impact glycemic control overall pathogenesis type 1 diabetes . The use CGM technology study allow u determine rapidity , consistency , sustainability response liraglutide .</brief_summary>
	<brief_title>Anti-diabetic Effects Liraglutide Adolescents Young Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Females male Type 1 diabetes ascertain islet autoantibody ( GAD65 and/or islet cell antibody ) 2 . Age 1530 year This age group choose complete puberty accompany physiologic phase increase insulin resistance . In addition , age group show increase selfmanagement capability . Extending age 30 year allow u include young adult , since type 1 diabetes frequently diagnose late teen early adult year . This study power detect difference liraglutide efficacy different age group may provide insight effectiveness teenage population , optimal glycemic control often challenge . 3 . Type 1 diabetes duration great 1 year ensure majority subject beyond partial remission period . 4 . Fasting Cpeptide level ≤ 0.3 ng/ml . 5 . HbA1c level equal less 9 % 6 . Insulin delivery CSII choice make facilitate adherence study drug also enable u homogeneous group analyze without analyze data covariants CSII vs. multiple daily injection therapy . 7 . Subjects willing wear CGM sensor perform home blood glucose monitoring four time daily symptom hypoglycemia . 8 . Subjects wellversed carbohydrate counting . 9 . BMI &lt; 95th % age gender . EXCLUSION CRITERIA : 1 . Previous exposure liraglutide 2 . History abdominal surgery 3 . History gastroparesis gastrointestinal reflux disease ; 4 . History acute chronic pancreatitis 5 . Cirrhosis hepatic disease define transaminase level &gt; 3 time normal 6 . Impaired renal function define serum creatinine &gt; 1.5 . 7 . HIV Hepatitis C positive status 8 . Pregnant/breastfeeding female 9 . Individuals steroidinduced cystic fibrosis relate diabetes 10 . Diabetic Ketoacidosis within 6 month study 11 . History severe hypoglycemia ( seizure , loss consciousness ) within 6 month study 12 . History medullary thyroid cancer MEN2 syndrome 13 . Any lifethreatening cardiac noncardiac disease 14 . Participation concurrent clinical trial participation trial within 30 day precede study period . 15 . Unable give inform consent/assent . 16 . Adolescents adult consider underweight base body mass index ( BMI ) : 1 . For adolescent : BMI le 5th percentile 2 . For adult : BMI 18.5</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>